Funded Biotechnology Startups
Across the 16 most recent biotechnology/healthcare/pharmaceuticals funding entries shown, one disclosed round stands out: Braveheart Bio’s $185M (Series A,…
Across the 16 most recent biotechnology/healthcare/pharmaceuticals funding entries shown, one disclosed round stands out: Braveheart Bio’s $185M (Series A, dated 2025-11-05). That $185M figure is well above the next-largest disclosed rounds, including Zag Bio’s $80M (Series A, 2025-10-29) and Azalea Therapeutics’ $65M (Series A, 2025-11-09), while multiple others cluster in the mid-teens to tens of millions (for example, Skeletalis at $8M on 2025-11-20 and Curadel Surgical Innovations at $14M on 2025-10-12).
Dates and geographies also cluster. Eight of the 16 rounds fall in November 2025 (from 2025-11-05 through 2025-11-28), with a noticeable concentration of UK and US entries around late October to mid-November (e.g., T-Therapeutics in Cambridge, UK at $32M on 2025-11-15; Excellergy in Palo Alto, US at $70M on 2025-10-13). Stage and disclosure skew toward labeled rounds: 10 entries are disclosed (amounts given), with 3 additional rounds marked “undisclosed” (Cartography Biosciences on 2026-05-06, Eliksa Therapeutics on 2025-10-28, and Immunofoco on 2025-10-16) and the remaining entries using “Series Unknown” labels (including Repair Biotechnologies on 2025-11-28 and Skeletalis on 2025-11-20). The window spans 2025-09-26 (Nuclide Therapeutics) through 2026-05-06 (Cartography Biosciences).
Most recent rounds
16 shownRelated listings
Frequently asked
Which disclosed round is the clear outlier, and how much larger is it than the next-largest disclosed amount?
Braveheart Bio’s disclosed $185M (Series A, 2025-11-05) is the only round above $100M in the 16 rows shown. The next-largest disclosed amounts sit in the $80M–$70M range, including Zag Bio’s $80M (2025-10-29) and Excellergy’s $70M (2025-10-13).
Do the most recent biotech rounds cluster in a narrow time window?
Yes. Eight of the 16 entries are dated in November 2025 (from 2025-11-05: Braveheart Bio through 2025-11-28: Repair Biotechnologies), while the earliest dated row is 2025-09-26 (Nuclide Therapeutics).
Are there city or country concentrations that stand out in this snapshot?
The list repeatedly surfaces Cambridge, UK and Cambridge, US as focal points: T-Therapeutics is in Cambridge, UK ($32M, 2025-11-15) and Zag Bio is in Cambridge, US ($80M, 2025-10-29), alongside multiple US-based rounds in the same late-October to November 2025 period (e.g., Azalea Therapeutics in Berkeley at $65M on 2025-11-09; Excellergy in Palo Alto at $70M on 2025-10-13).
How dominant are specific stages among disclosed rounds, and what share are unlabeled or undisclosed?
Among the rows shown, Series A appears frequently with disclosed amounts (e.g., T-Therapeutics $32M on 2025-11-15; Azalea Therapeutics $65M on 2025-11-09; Braveheart Bio $185M on 2025-11-05; Zag Bio $80M on 2025-10-29; Excellergy $70M on 2025-10-13). In parallel, three entries are marked “undisclosed” (Cartography Biosciences on 2026-05-06; Eliksa Therapeutics on 2025-10-28; Immunofoco on 2025-10-16), and several others use “Series Unknown” (e.g., Repair Biotechnologies on 2025-11-28 and Skeletalis on 2025-11-20).
Which entries fall in the tight late-October to late-November cluster and include notable deal sizes?
In the late-October to late-November run, disclosed rounds include Azalea Therapeutics $65M (2025-11-09), Braveheart Bio $185M (2025-11-05), Zag Bio $80M (2025-10-29), and Excellergy $70M (2025-10-13). Smaller but still disclosed deals in the same window include Curadel Surgical Innovations $14M (2025-10-12) and Skeletalis $8M (2025-11-20).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.